Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neck
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
18 Feb 2026: Trial registered, NCT07418034
19 Oct 2026: Trial started, NCT07418034
The trials
NCT07418034: A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
State
Under way
Phase
Phase 2
People
132 planned
Started
19 Oct 2026
Primary completion
May 2031
Arms
Selective dose de-escalation of nodAl VolumEs at minimal Risk and primary site Disease
Results
None posted
18 Feb 2026: Trial registered
19 Oct 2026: Trial started
How the status changed
19 Nov 2026: First set: Phase 2 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.